Where care claims fall short
An unanswered question can be enough reason to stop and ask for the record before deciding.
In September 2026, a registration or drug listing with FDA, the US medicine-review agency, is not a product approval.
FDA also says an NDC, the identification number in its drug directory, is not proof of approval.
Ask for the actual approval record, not another badge.
Medical-board guidance · treatment selection
Under medical-board guidance adopted in May 2026, the care standard requires more than a patient picking treatment from a menu.
Ask how the doctor considers your problem and how you can ask follow-up questions. Doctors must follow the rules of the state where they treat you.
Read the guidance behind this checkIn its review checked in September 2026, FDA found that most BPC-157 test certificates it examined reported only how much of the material was BPC-157. They did not report checks and limits for unwanted substances in it.
For injections, FDA identifies tests for germs, toxins made by bacteria and stray particles in the medicine as key quality checks. Toxins are harmful substances.
A high purity figure alone does not show that these checks were done.
A certificate of analysis is a report of tests on material. Ask the pharmacist to explain which tests were done, what they found and which batch they cover.
As of September 2026, a research-only label does not mean FDA has reviewed a BPC-157 product for people.
Ask for the medicine’s status and source in clear words. The research label does not answer either question.
The World Anti-Doping Agency’s rules in force in September 2026 prohibit BPC-157 during and between competitions.
If you compete, ask your sport’s medical contact which rules apply to you.
Read world sport’s current listFDA includes implausibly deep discounts among online-pharmacy warning signs, but a low price alone is not a verdict on a service.
Read it alongside the licence, assessment and source checks. Ask for the regular charge and the cancellation terms before agreeing.